Central germline testing confirmed that 388 of the 391 patients had a BRCA1/2 mutation, 1 had a BRCA variant of uncertain significance, and 2 had wild-type BRCA. Testing at Foundation Medicine showed that the 2 patients with wild-type BRCA on central germline testing had somatic BRCA mutations

The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olaparib than with placebo.